hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06315452, orgStudyIdInfo id: PremaVitaD, briefTitle: FREQUENCY OF VITAMIN D DEFICIENCY IN PREMATURE NEWBORN BORN BEFORE 32 WEEKS AND/OR WITH A BIRTH WEIGHT UNDER 1500g, acronym: PremaVitaD, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-02-01, primaryCompletionDateStruct date: 2024-02-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Fondation Hôpital Saint-Joseph, class: OTHER, descriptionModule briefSummary: Vitamin D plays an important role in phosphocalcic metabolism and bone homeostasis in newborns. Premature newborns are at risk of vitamin D deficiency and may require supplementation. In this context, the French Society of Pediatrics (Société Française de Pédiatrie) recommends systematic vitamin D testing at 1 month.The aim of this study was to determine the frequency of vitamin D deficiency in premature newborns., conditionsModule conditions: Vitamin D Deficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 110, type: ACTUAL, outcomesModule primaryOutcomes measure: Vitamine D deficiency frequency, secondaryOutcomes measure: vitamine D deficiency and maternal or feotal caracteristics, secondaryOutcomes measure: vitamine D deficiency and premature newborn comorbidities, secondaryOutcomes measure: effect of supplementation, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 6 Months, stdAges: CHILD, contactsLocationsModule locations facility: Hôpital Saint Joseph, city: Paris, zip: 75014, country: France, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06315439, orgStudyIdInfo id: Multi-RELAMI, briefTitle: Digital Confocal Microscopy for Real-time Diagnosis of Pancreatic Solid Lesion, acronym: Multi-RELAMI, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2023-11-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Campus Bio-Medico University, class: OTHER, descriptionModule briefSummary: Endoscopic ultrasound-guided (EUS) tissue acquisition is the current standard of care for the diagnosis of pancreatic solid lesions but it is burdened by a non-negligible risk of non-diagnostic or inconclusive results.Ex-vivo fluorescence confocal laser microscopy (FCM) with MAVIG VivaScope® 2500M-G4 could allow real time assessment of adequacy and diagnosis of the sample., conditionsModule conditions: Pancreas Adenocarcinoma, conditions: Endoscopic Ultrasound, conditions: Digital Pathology, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 78, type: ACTUAL, armsInterventionsModule interventions name: Endoscopic ultrasound fine needle biopsy, outcomesModule primaryOutcomes measure: Diagnostic accuracy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Campus Bio Medico, city: Rome, state: Roma, zip: 00191, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06315426, orgStudyIdInfo id: GR1802-011, briefTitle: A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR)., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Genrix (Shanghai) Biopharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease., conditionsModule conditions: Allergic Rhinitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: GR1802 injection, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change from Baseline in rTNSS( reflective total nasal symptom scores), secondaryOutcomes measure: Change from Baseline in rTOSS( reflective total ocular symptom scores), secondaryOutcomes measure: Change from Baseline in rTNSS, secondaryOutcomes measure: Mean change from baseline in iTNSS(instantaneous total nasal symptom scores), secondaryOutcomes measure: Mean change from baseline in iTOSS(instantaneous total ocular symptom scores), secondaryOutcomes measure: Change from baseline in VAS(Visual Analog Scale) score, secondaryOutcomes measure: Change from baseline in RQLQ(Rhinoconjunctivitis Quality of Life Questionnaire) scores, secondaryOutcomes measure: Adverse events (AEs), secondaryOutcomes measure: Immunogenicity characteristics, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315413, orgStudyIdInfo id: Composite plug vs d-PTFE, briefTitle: Composite Plug vs d-PTFE Membrane in Socket Preservation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The aim of the current study is to compare the effect socket sealing with flowable resin composite compared to dense polytetrafluoroethylene membrane after filling the extraction site with xenograft particles in terms of soft and hard tissue changes, procedural time, post operative pain, patients' satisfaction, and cost effectiveness., conditionsModule conditions: Alveolar Bone Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Socket preservation using xenograft and composite plug, interventions name: Socket preservation using xenograft and intentionally exposed d-PTFE, outcomesModule primaryOutcomes measure: Change in horizontal bone dimension, secondaryOutcomes measure: Change in Vertical bone dimension, secondaryOutcomes measure: Keratinized tissue thickness, secondaryOutcomes measure: Procedural time, secondaryOutcomes measure: Post-operative pain, secondaryOutcomes measure: Patient Satisfaction, secondaryOutcomes measure: Incidence of complications, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of oral and dental medicine, Cairo university, city: Cairo, zip: 4240310, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06315387, orgStudyIdInfo id: GIB-01-01-2023, briefTitle: Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-04, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Valenta Pharm JSC, class: INDUSTRY, descriptionModule briefSummary: Study of safety, tolerability and pharmacokinetic parameters of different doses of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) in healthy volunteers, conditionsModule conditions: Cholecystitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: 4-MUST, 1 tablet, interventions name: 4-MUST, 2 tablets, interventions name: 4-MUST, 3 tablets, outcomesModule primaryOutcomes measure: Pharmacokinetics - Cmax, primaryOutcomes measure: Pharmacokinetics - tmax, primaryOutcomes measure: Pharmacokinetics - AUC0-t, primaryOutcomes measure: Pharmacokinetics - AUC0-inf, primaryOutcomes measure: Pharmacokinetics - AUCextr, primaryOutcomes measure: Pharmacokinetics - t1/2, primaryOutcomes measure: Pharmacokinetics - kel, primaryOutcomes measure: Pharmacokinetics - MRT, primaryOutcomes measure: Pharmacokinetics - Vd, primaryOutcomes measure: Pharmacokinetics - CL, primaryOutcomes measure: Pharmacokinetics - number of terminal timepoints, secondaryOutcomes measure: Adverse event type, secondaryOutcomes measure: Adverse event frequency, secondaryOutcomes measure: Adverse event severety, secondaryOutcomes measure: Drop-outs associated with adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Limited Liability Company "Medical Center Eco-Safety", status: RECRUITING, city: St. Petersburg, zip: 19119, country: Russian Federation, contacts name: Vasiliy Vasilyuk, MD,PhD, Prof., role: CONTACT, phone: +7 (812) 500-52-03, phoneExt: 5001, email: vasilyuk_vb@ecosafety.ru, geoPoint lat: 59.93863, lon: 30.31413, hasResults: False
protocolSection identificationModule nctId: NCT06315374, orgStudyIdInfo id: FJUH112267, briefTitle: 3D-Printed Aerosolized Medication Delivery Assist Device in Patients With Chronic Respiratory Diseases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Fu Jen Catholic University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate the auxiliary benefits of three-dimensional printed activating assistive devices for soft-mist inhaler on patients' utilization habit., conditionsModule conditions: Chronic Pulmonary Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Use soft mist inhaler, interventions name: Use soft mist inhaler with a 3D assistive device, outcomesModule primaryOutcomes measure: satisfaction survey, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fu Jen Catholic University Hospital, Fu Jen Catholic University, city: New Taipei City, zip: 24352, country: Taiwan, contacts name: Ke-Yun Chao, PhD, role: CONTACT, phone: +886-905-301-879, email: ck_qq@hotmail.com, contacts name: Ke-Yun Chao, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 25.01111, lon: 121.44583, hasResults: False
protocolSection identificationModule nctId: NCT06315335, orgStudyIdInfo id: UP0118, briefTitle: A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-07-29, completionDateStruct date: 2025-07-29, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: UCB Biopharma SRL, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is investigate the safety, tolerability and pharmacokinetic of UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy Caucasian and Japanese participants., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: UCB9741, interventions name: Placebo, outcomesModule primaryOutcomes measure: Occurrence of TEAEs, primaryOutcomes measure: Occurrence of treatment-emergent SAEs, secondaryOutcomes measure: Cmax, secondaryOutcomes measure: AUC0-t, secondaryOutcomes measure: AUCinf, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315322, orgStudyIdInfo id: EP0224, secondaryIdInfos id: 2023-508095-11-00, type: REGISTRY, domain: EU Trial Number, secondaryIdInfos id: U1111-1303-1174, type: OTHER, domain: Universal Trial Number, briefTitle: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2029-02-28, completionDateStruct date: 2029-02-28, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: UCB Biopharma SRL, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy., conditionsModule conditions: Childhood Absence Epilepsy, conditions: Juvenile Absence Epilepsy, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Brivaracetam Film-coated tablet, interventions name: Brivaracetam oral solution, outcomesModule primaryOutcomes measure: Incidence of treatment-emergent adverse events (TEAEs) during the study, primaryOutcomes measure: Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of investigational medicinal product (IMP) during the study, secondaryOutcomes measure: Incidence of serious adverse events (SAEs) during the study, secondaryOutcomes measure: Incidence of IMP related TEAEs during the study, eligibilityModule sex: ALL, minimumAge: 2 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315309, orgStudyIdInfo id: IRB-300012281 (UAB 23146), briefTitle: Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-29, primaryCompletionDateStruct date: 2025-10-29, completionDateStruct date: 2027-02, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development and/or improve severity of acute and/or chronic GVHD., conditionsModule conditions: GVHD,Acute, conditions: Acute Leukemia, conditions: Myelodysplastic Syndromes, conditions: Myeloproliferative Disorders, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 29, type: ESTIMATED, armsInterventionsModule interventions name: ATG Combined with Tacrolimus and Mini Methotrexate, outcomesModule primaryOutcomes measure: To estimate the therapeutic success of 2-step ATG dosing platform in patients undergoing reduced intensity allogeneic transplantation for treatment of hematologic malignances, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Zaid S Al Kadhimi, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Manuel Espinoza-Gutarra, MD, role: SUB_INVESTIGATOR, contacts name: Omer Jamy, MD, role: SUB_INVESTIGATOR, contacts name: Donna Salzman, MD, role: SUB_INVESTIGATOR, contacts name: Razan Mohty, MD, role: SUB_INVESTIGATOR, contacts name: Lauren Shea, MD, role: SUB_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06315270, orgStudyIdInfo id: 24K040-001, briefTitle: To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2029-03-20, completionDateStruct date: 2029-03-20, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: The First Hospital of Jilin University, class: OTHER, descriptionModule briefSummary: This project proposes to elucidate the functional impact of T cells in cancer progression and treatment through a comprehensive TCR profiling study and a longitudinal cohort study in patients with advanced epithelial ovarian cancer. Our findings aim to provide clinical insights for monitoring treatment response in a non-invasive way and demonstrate the association of TCR diversity with clinical outcomes and the potential role of TCR profiling in cancer prognosis., conditionsModule conditions: Epithelial Ovarian Cancer, conditions: Stage III Ovarian Cancer, conditions: Stage IV Ovarian Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Analysis of TCR genealogy data, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315257, orgStudyIdInfo id: J23105sIRB, secondaryIdInfos id: IRB00388854, type: OTHER, domain: Johns Hopkins, briefTitle: A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2026-08, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy., conditionsModule conditions: Cervical Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: PVX7, outcomesModule primaryOutcomes measure: Safety of PVX7 as assessed by adverse events, primaryOutcomes measure: Feasibility of PVX7, secondaryOutcomes measure: Cellular Immune Response, secondaryOutcomes measure: Immune Response, secondaryOutcomes measure: Presence of circulating HPV DNA, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315244, orgStudyIdInfo id: 2558, briefTitle: Perforating Cutaneous Nerve Injection Efficacy in Chronic Coccydynia: A Randomized, Double-Blind Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Sisli Hamidiye Etfal Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Interventions targeting the perforating cutaneous nerve are relatively new to the literature, with a safe side-effect profile but lacking high-quality studies. Their effectiveness remains at the level of case presentations. According to the hypothesis expressed in these publications, coccydynia might be an overlooked cause due to the compression of the perforating cutaneous nerve where it pierces the sacrotuberous ligament and becomes superficial. Ultimately, it is hypothesized that injection of dextrose into this ligament and the sensory area of this nerve will resolve these symptoms due to nerve entrapment, similar to other entrapment neuropathies treated with 5% dextrose, like carpal tunnel syndrome., conditionsModule conditions: Coccyx Disorder, conditions: Coccyx Injury, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: US Guided Perineural Injection and Neuroprolotherapy, outcomesModule primaryOutcomes measure: Effectiveness of Perforating Cutaneous Nerve Injection, secondaryOutcomes measure: Change in Pressure Pain Threshold, secondaryOutcomes measure: Change in Quality of Life, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Sisli Hamidiye Etfal Training and Research Hospital, status: RECRUITING, city: Istanbul, zip: 34371, country: Turkey, contacts name: Enes Efe Is, MD, role: CONTACT, phone: +902123735000, email: enefeis@gmail.com, contacts name: Enes Efe Is, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False